SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

Ion Beam Applications

Closed

12.28 0.82

Overview

Share price change

24h

Current

Min

11.58

Max

12.34

Key metrics

By Trading Economics

Income

30M

20M

Sales

85M

292M

P/E

Sector Avg

38.71

51.198

Dividend yield

1.4

Profit margin

6.719

Employees

2,118

EBITDA

24M

24M

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.40%

2.40%

Next Earnings

28 Aug 2025

Market Stats

By TradingEconomics

Market Cap

46M

355M

Previous open

11.46

Previous close

12.28

Ion Beam Applications Chart

Past performance is not a reliable indicator of future results.

Related News

11 Sept 2024, 06:28 UTC

Acquisitions, Mergers, Takeovers

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Peer Comparison

Price change

Ion Beam Applications Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.